Spectrum Asset Management Inc. NB CA Takes $2.77 Million Position in Illumina, Inc. $ILMN

Spectrum Asset Management Inc. NB CA bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the first quarter, HoldingsChannel.com reports. The firm bought 22,436 shares of the life sciences company’s stock, valued at approximately $2,765,000.

Other large investors have also modified their holdings of the company. Elyxium Wealth LLC acquired a new stake in Illumina during the 4th quarter valued at $25,000. Creative Capital Management Investments LLC raised its holdings in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Illumina in the fourth quarter valued at $26,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina during the fourth quarter valued at $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,003,769 shares of company stock worth $155,710,908. Corporate insiders own 2.90% of the company’s stock.

Illumina Price Performance

ILMN opened at $176.55 on Friday. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $182.84. The company’s 50 day simple moving average is $149.62 and its 200 day simple moving average is $137.66. The stock has a market capitalization of $26.71 billion, a PE ratio of 32.10, a P/E/G ratio of 3.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 5.21 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on ILMN. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Canaccord Genuity Group lowered their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a report on Friday, May 1st. Citigroup boosted their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Finally, Sanford C. Bernstein began coverage on shares of Illumina in a research report on Friday. They set a “market perform” rating and a $185.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $146.00.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.